AG
APLS

Algert Global’s Apellis Pharmaceuticals APLS Stock Holding History

Algert Global’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-109,733
Closed -$2.76M – 1153
2025
Q4 		$2.76M Hold
109,733
– – 0.04% 620
2025
Q3 		$2.48M Sell
109,733
-44,380
-29% -$1.04M 0.04% 623
2025
Q2 		$2.67M Sell
154,113
-184,500
-54% -$3.42M 0.06% 543
2025
Q1 		$7.41M Buy
338,613
+56,328
+20% +$1.56M 0.18% 155
2024
Q4 		$9.01M Buy
282,285
+199,874
+243% +$6.01M 0.21% 136
2024
Q3 		$2.38M Sell
82,411
-41,217
-33% -$1.53M 0.06% 499
2024
Q2 		$4.74M Buy
123,628
+71,650
+138% +$3.24M 0.16% 187
2024
Q1 		$3.06M Buy
51,978
+11,049
+27% +$704K 0.12% 290
2023
Q4 		$2.45M Sell
40,929
-19,375
-32% -$983K 0.1% 352
2023
Q3 		$2.29M Buy
60,304
+32,505
+117% +$1.43M 0.11% 320
2023
Q2 		$2.53M Sell
27,799
-14,900
-35% -$1.29M 0.11% 315
2023
Q1 		$2.82M Buy
42,699
+9,468
+28% +$546K 0.13% 234
2022
Q4 		$1.72M Hold
33,231
– – 0.1% 347
2022
Q3 		$2.27M Buy
33,231
+1,847
+6% +$109K 0.14% 234
2022
Q2 		$1.42M Buy
31,384
+11,121
+55% +$507K 0.11% 329
2022
Q1 		$1.03M Buy
20,263
+12,896
+175% +$569K 0.07% 513
2021
Q4 		$348K Buy
+7,367
New +$290K 0.04% 677
2021
Q2 		– Sell
-8,979
Closed -$385K – 425
2021
Q1 		$385K Sell
8,979
-23,424
-72% -$1.11M 0.12% 257
2020
Q4 		$1.85M Sell
32,403
-3,172
-9% -$134K 0.53% 50
2020
Q3 		$1.07M Sell
35,575
-12,560
-26% -$375K 0.34% 111
2020
Q2 		$1.57M Sell
48,135
-1,750
-4% -$56.2K 0.53% 49
2020
Q1 		$1.34M Buy
+49,885
New +$1.77M 0.56% 37

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Algert Global's APLS Position: Q1 2026 in Review

Algert Global sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 109,733 shares — an estimated $2.76M sold.

Algert Global first reported a position in APLS in Q1 2020 and held it in 22 quarters. The position peaked at $9.01M in Q4 2024. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Algert Global reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Algert Global sold 109,733 Apellis Pharmaceuticals shares in Q1 2026, an estimated $2.76M.
  • Algert Global first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 22 quarters.
  • Algert Global's Apellis Pharmaceuticals position peaked at $9.01M in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.